GDC-0214 NEW
Price | $89 | $202 | $298 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-08 |
Product Details
Product Name: GDC-0214 | CAS No.: 1831144-46-7 |
Purity: 98.54% | Supply Ability: 10g |
Release date: 2024/11/08 |
Product Introduction
Bioactivity
名稱 | GDC-0214 |
描述 | GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno). |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 9 mg/mL (14.7 mM) |
關鍵字 | GDC-0214 | GDC0214 | GDC 0214 |
相關產(chǎn)品 | Delgocitinib | Fedratinib | Deucravacitinib | RO8191 | Ruxolitinib | Tofacitinib Citrate | CEP-33779 | Ruxolitinib phosphate | JAK-IN-10 | Baricitinib | WHI-P97 | Tofacitinib |
相關庫 | 抗肺癌化合物庫 | 抗胰腺癌化合物庫 | 經(jīng)典已知活性庫 | 激酶抑制劑庫 | JAK-STAT 化合物庫 | 血管生成庫 | 抑制劑庫 | 干細胞分化化合物庫 | 抗前列腺癌化合物庫 | 免疫/炎癥分子化合物庫 | 已知活性化合物庫 | 抗肝癌化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$518.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$0.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$0.00/10mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-03-29 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY